Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease
The purpose of this study is to determine whether Lingzhi (Ganoderma), a widely used traditional Chinese Medicine is effective and safe in the treatment of Parkinson's disease when combined use with L-dopa.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCI|
- Motor Function
- Quality of Daily Life
|Study Start Date:||September 2005|
|Study Completion Date:||February 2008|
This study is to focus on the effects of Lingzhi on non-motor symptoms of Parkinson's diseases as the primary outcome and on delaying the disease progression using the delay start design as the secondary outcome measurement. Two dosage groups and one placebo control group with total 360 subjects will be recruited. The treatment is one year.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00224263
|Principal Investigator:||Piu Chan, MD, PhD||Xuanwu Hospital, Beijing|